Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTO3HT7)

• DTT Name: Transforming growth factor beta (TGFB)
• Synonyms: TGF-beta
• Gene Name: NO-GeName
• DTT Type: Clinical trial target; [1]
• Related Disease:
  Brain cancer [ICD-11: 2A00]
  Chronic kidney disease [ICD-11: GB61]
  Myeloproliferative neoplasm [ICD-11: 2A20]
  Non-small cell lung cancer [ICD-11: 2C25]
  Pancreatic cancer [ICD-11: 2C10]
  Ureteral cancer [ICD-11: 2C92]
  Myelodysplastic syndrome [ICD-11: 2A37]
  Anemia [ICD-11: 3A00-3A9Z]
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]
• UniProt ID: NOUNIPROTAC
• TTD ID: T06011

Molecular Interaction Atlas (MIA) of This DTT

10 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bintrafusp alfa	DMB9LRJ	Non-small cell lung cancer	2C25	Phase 2	[2]
Fresolimumab	DMFZ084	Brain cancer	2A00	Phase 2	[3]
LY2382770	DMH3YKJ	Diabetic kidney disease	GB61.Z	Phase 2	[4]
M7824	DMJCULI	Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]
NIS793	DM8LBYT	Pancreatic ductal carcinoma	2C10.0	Phase 2	[1]
TEW-7197	DM2LBC3	Myeloproliferative neoplasm	2A20	Phase 2	[1]
ACE-011	DMJ36YH	Anemia	3A00-3A9Z	Phase 1	[5]
AVID200	DMZ39T6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
BCA101	DMM0VBU	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
GS-1423	DMS25DL	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]

1 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SHP-627	DMHAONP	Cardiac arrest	MC82	Preclinical	[9]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial. J Thorac Oncol. 2020 Jul;15(7):1210-1222.
• [3] Focal Irradiation and Systemic TGF Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 Jun 1;24(11):2493-2504.
• [4] A phase I dose-escalation study to a predefined dose of a transforming growth factor-1 monoclonal antibody (TM1) in patients with metastatic cancer. Int J Oncol. 2014 Dec;45(6):2221-31.
• [5] Clinical pipeline report, company report or official report of Acceleron Pharma (2011).
• [6] TGF signaling underlies hematopoietic dysfunction and bone marrow failure in Shwachman-Diamond Syndrome. J Clin Invest. 2019 Jun 18;129(9):3821-3826.
• [7] ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
• [8] Clinical pipeline report, company report or official report of Agenus.
• [9] Drugs and Targets in Fibrosis. Front Pharmacol. 2017 Nov 23;8:855.